Today, Jan. 23, 2026, profit taking and fresh glioblastoma survival data weighed on a soaring biotech stock. ImmunityBio ( ...
Stocktwits on MSN
IBRX stock gains pre-market after a volatile trading session following phase 2 glioblastoma trial update: Retail backs ImmunityBio’s cancer research
Shiong added that “median overall survival” is a scientific endpoint that is used to measure survival, which currently stands ...
ImmunityBio stock rose 19.8% after FDA meeting on ANKTIVA bladder cancer treatment. Company to submit additional data within ...
At study entry, patients demonstrated immune compromise consistent with prior standard of care, including radiation and alkylating chemotherapy. The baseline mean absolute lymphocyte count (ALC) was ...
Add Yahoo as a preferred source to see more of our stories on Google. ImmunityBio's Anktiva is already approved in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Image credit: Tigarto / ...
I maintain a Hold rating on ImmunityBio as Anktiva shows strong NMIBC data but the commercial uptake remains slow and uncertain. IBRX's Q2 revenues rose to $26.4M, but accumulated losses and lack of ...
ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision ...
Adenosine deaminase acting on RNA (ADAR) is the enzyme responsible for adenosine-to-inosine (A-to-I) RNA editing, a process essential for regulating how cells respond to double-stranded RNA. ADAR1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results